Comparative Pharmacology
Head-to-head clinical analysis: HIPPUTOPE versus SODIUM IODIDE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPUTOPE versus SODIUM IODIDE I 123.
HIPPUTOPE vs SODIUM IODIDE I 123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPUTOPE is a diagnostic agent used to assess renal function. It is a radiolabeled compound that undergoes glomerular filtration and tubular secretion, allowing measurement of renal plasma flow and tubular function via imaging.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
100-300 microcuries (3.7-11.1 MBq) intravenous, single dose for renal imaging.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
None Documented
None Documented
Terminal elimination half-life is 1.5–2.5 hours; prolonged to 6–12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Primarily renal excretion (approximately 90% as unchanged drug via glomerular filtration), with minor biliary/fecal elimination (<10%).
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical